title: [Therapy with vasopressin receptor antagonists: the aquaretics].
abstract: Aquaretic drugs, by definition, can induce an increase in urinary volume and urinary free water associated with a decreased urinary osmolarity with a consequent increase in plasma sodium. This enhanced diuresis is not accompanied by an increased loss of electrolytes, whereas traditional diuretics have the opposite, so-called saluretic effect. Aquaretics belong to a family of vasopressin receptor antagonists, V2 in particular, that regulate tubular water reabsorption. Several studies have confirmed their utility in the treatment of hyponatremic states associated with water retention such as heart failure, cirrhosis related ascites and SIADH. Furthermore, new applications may include the treatment of arterial hypertension, polycystic kidney disease, glaucoma and Meniere's syndrome.
authors: Cattedra di Nefrologia, Dipartimento di Medicina Interna, Universita' degli Studi, Messina - Italy.
authors: M
authors: M
authors: Buemi
authors: D
authors: D
authors: Bolignano
authors: G
authors: G
authors: Coppolino
authors: A
authors: A
authors: Sturiale
authors: S
authors: S
authors: Campo
authors: E
authors: E
authors: Crasci'
authors: C
authors: C
authors: Aloisi
authors: N
authors: N
authors: Frisina
mesh_terms: D065092:Antidiuretic Hormone Receptor Antagonists / Q000627:therapeutic use; D004231:Diuresis; D004232:Diuretics / Q000627:therapeutic use; D006333:Heart Failure / Q000188:drug therapy; D006801:Humans; D007010:Hyponatremia / Q000188:drug therapy; D007177:Inappropriate ADH Syndrome / Q000188:drug therapy
chemical_list: D065092:Antidiuretic Hormone Receptor Antagonists; D004232:Diuretics